These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

366 related items for PubMed ID: 18211131

  • 1. Gender differences in 2 clinical trials of adults with attention-deficit/hyperactivity disorder: a retrospective data analysis.
    Robison RJ, Reimherr FW, Marchant BK, Faraone SV, Adler LA, West SA.
    J Clin Psychiatry; 2008 Feb; 69(2):213-21. PubMed ID: 18211131
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Relationships Between Functional Outcomes and Symptomatic Improvement in Atomoxetine-Treated Adult Patients with Attention-Deficit/Hyperactivity Disorder: Post Hoc Analysis of an Integrated Database.
    De Bruyckere K, Bushe C, Bartel C, Berggren L, Kan CC, Dittmann RW.
    CNS Drugs; 2016 Jun; 30(6):541-58. PubMed ID: 27224994
    [Abstract] [Full Text] [Related]

  • 4. Atomoxetine treatment of attention-deficit/hyperactivity disorder in young adults with assessment of functional outcomes: a randomized, double-blind, placebo-controlled clinical trial.
    Durell TM, Adler LA, Williams DW, Deldar A, McGough JJ, Glaser PE, Rubin RL, Pigott TA, Sarkis EH, Fox BK.
    J Clin Psychopharmacol; 2013 Feb; 33(1):45-54. PubMed ID: 23277268
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Atomoxetine improved attention in children and adolescents with attention-deficit/hyperactivity disorder and dyslexia in a 16 week, acute, randomized, double-blind trial.
    Wietecha L, Williams D, Shaywitz S, Shaywitz B, Hooper SR, Wigal SB, Dunn D, McBurnett K.
    J Child Adolesc Psychopharmacol; 2013 Nov; 23(9):605-13. PubMed ID: 24206099
    [Abstract] [Full Text] [Related]

  • 10. Once-daily atomoxetine for adult attention-deficit/hyperactivity disorder: a 6-month, double-blind trial.
    Adler LA, Spencer T, Brown TE, Holdnack J, Saylor K, Schuh K, Trzepacz PT, Williams DW, Kelsey D.
    J Clin Psychopharmacol; 2009 Feb; 29(1):44-50. PubMed ID: 19142107
    [Abstract] [Full Text] [Related]

  • 11. Atomoxetine Increased Effect over Time in Adults with Attention-Deficit/Hyperactivity Disorder Treated for up to 6 Months: Pooled Analysis of Two Double-Blind, Placebo-Controlled, Randomized Trials.
    Wietecha LA, Clemow DB, Buchanan AS, Young JL, Sarkis EH, Findling RL.
    CNS Neurosci Ther; 2016 Jul; 22(7):546-57. PubMed ID: 26922462
    [Abstract] [Full Text] [Related]

  • 12. Long-term open-label response to atomoxetine in adult ADHD: influence of sex, emotional dysregulation, and double-blind response to atomoxetine.
    Marchant BK, Reimherr FW, Halls C, Williams ED, Strong RE, Kondo D, Soni P, Robison RJ.
    Atten Defic Hyperact Disord; 2011 Sep; 3(3):237-44. PubMed ID: 21442440
    [Abstract] [Full Text] [Related]

  • 13. Validation of the adult attention-deficit/hyperactivity disorder quality-of-life scale in European patients: comparison with patients from the USA.
    Brod M, Adler LA, Lipsius S, Tanaka Y, Heinloth AN, Upadhyaya H.
    Atten Defic Hyperact Disord; 2015 Jun; 7(2):141-50. PubMed ID: 25563210
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Atomoxetine versus placebo in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: a double-blind, randomized, multicenter trial in Germany.
    Dittmann RW, Schacht A, Helsberg K, Schneider-Fresenius C, Lehmann M, Lehmkuhl G, Wehmeier PM.
    J Child Adolesc Psychopharmacol; 2011 Apr; 21(2):97-110. PubMed ID: 21488751
    [Abstract] [Full Text] [Related]

  • 17. Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial.
    Kelsey DK, Sumner CR, Casat CD, Coury DL, Quintana H, Saylor KE, Sutton VK, Gonzales J, Malcolm SK, Schuh KJ, Allen AJ.
    Pediatrics; 2004 Jul; 114(1):e1-8. PubMed ID: 15231966
    [Abstract] [Full Text] [Related]

  • 18. Quality of life assessment in adult patients with attention-deficit/hyperactivity disorder treated with atomoxetine.
    Adler LA, Sutton VK, Moore RJ, Dietrich AP, Reimherr FW, Sangal RB, Saylor KE, Secnik K, Kelsey DK, Allen AJ.
    J Clin Psychopharmacol; 2006 Dec; 26(6):648-52. PubMed ID: 17110824
    [Abstract] [Full Text] [Related]

  • 19. Twenty-four-week treatment with extended release methylphenidate improves emotional symptoms in adult ADHD.
    Rösler M, Retz W, Fischer R, Ose C, Alm B, Deckert J, Philipsen A, Herpertz S, Ammer R.
    World J Biol Psychiatry; 2010 Aug; 11(5):709-18. PubMed ID: 20353312
    [Abstract] [Full Text] [Related]

  • 20. Open-label, dose-titration tolerability study of atomoxetine hydrochloride in Korean, Chinese, and Taiwanese adults with attention-deficit/hyperactivity disorder.
    Takahashi M, Goto T, Takita Y, Chung SK, Wang Y, Gau SS.
    Asia Pac Psychiatry; 2014 Mar; 6(1):62-70. PubMed ID: 23857916
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.